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OBJECTIVES: A once-weekly formulation of exenatide (EQW) received positive
opinion from the EMA in April 2011 for the treatment of type 2 diabetes. No head-
to-head study of EQW and liraglutide 1.2mg once-daily (the dose recommended by
NICE) has been conducted therefore a network meta-analysis to compare EQW to
liraglutide 1.2mg in terms of effect on HbA1c was performed.METHODS:A system-
atic review was conducted to identify randomized controlled trials of EQW and
liraglutide (1.2mg and 1.8mg) of 24 weeks or more, and the common comparators
insulin glargine and exenatide bid to allow a network meta-analysis. Additionally,
the manufacturing companies were asked to provide any unpublished data from
studies meeting the criteria. 22 studies including 10,816 patients met our inclusion
criteria. Treatments were compared in terms of mean difference in HbA1c relative
to placebo. Additionally, EQW was compared to both doses of liraglutide, and lira-
glutide 1.2mg was compared to liraglutide 1.8mg. RESULTS: Results from random
effects models controlling for baseline HbA1c are presented. Analysis of change in
HbA1c produced estimated mean differences relative to placebo of -1.15% (95% CI
-1.31, -1.00) for EQW, -1.01% (95% CI -1.18, -0.85) for liraglutide 1.2mg, and -1.18%
(95% CI -1.32%, -1.04%) for liraglutide 1.8mg. The comparison of EQW to liraglutide
1.2mg and liraglutide 1.8mg showed a mean difference (95% CI) of -0.14% (-0.34,
0.06) and 0.03% (-0.14, 0.18) respectively. Liraglutide 1.2mg compared to liraglutide
1.8mg showed a mean difference in HbA1c of 0.17% (0.02, 0.30). Results were con-
sistent when controlling for use of background antihyperglyemic medications.
CONCLUSIONS: Our analysis suggests EQW and both doses of liraglutide have
robust and similar efficacy with respect to lowering of HbA1c. Further analysis is
warranted to investigate the inconsistency between the direct and indirect evi-
dence with respect to the comparison of EQW to liraglutide 1.8mg.
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OBJECTIVES: To evaluate weight change and glycemic control in patients age 65
with type 2 diabetes (T2DM) in a usual-care setting. METHODS: Treatment naïve
patients age 65 years with T2DM and a prescription (index date) for a sulfonylurea
(SU), metformin (MET), thiazolidinedione (TZD), GLP-1 agonist (GLP-1), or DPP-4
inhibitor (DPP-4) were identified in an electronic medical record database from
1/1/2000 to 6/30/2010. HbA1c 7% or 7% and weight gain or loss of 3% were
assessed 1 year post-index. Logistic regression identified the likelihood of weight
loss and attaining HbA1c goal by antidiabetic drug class, controlling for baseline
HbA1c and weight, and for weight change for HbA1c goal attainment. RESULTS: Of
12,473 patients, 46.4% were male and the mean age was 71.7 (3.9) years. At base-
line 26.7% had HbA1c7.0%; mean weight 86.8 (18.7) kg. Breakdown by drug class
was: SU - 31.0%, MET - 55.0%, TZD - 11.6%, DPP-4 - 1.9%, and GLP-1 - 0.6%. At 1 year,
34.8% lost3% of body weight and 46.5% had an HbA1c7.0%. In logistic regression
analyses, MET and DPP-4 (OR 1.4 and 1.36; p.05) were associated weight loss
relative to SU, TZDs were negatively associated with weight loss (OR 0.86; p.05),
and GLP-1 did not differ (OR 1.55; p0.08). Patients who lost weight were 2.26 times
as likely as those who did not to attain HbA1c goal (p.05). Drug class was not
associated with HbA1c goal attainment (p0.05). CONCLUSIONS: In patients with
T2DM age 65, those who lost weight were more likely to attain HbA1C goal than
those who did not. MET and DPP-4 were associated with weight loss vs. SU, but drug
class was not associated with HbA1C goal attainment. These findings support
guideline recommendations to consider weight-effect properties of antidiabetics
in treating T2DM with data specific to patients age 65.
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OBJECTIVES: This post hoc analysis analyzed the number of patients needed to be
treated (NNT) with the GLP-1 receptor agonist exenatide once weekly (ExQW) vs
titrated insulin glargine (IG) over 26 weeks to allow one additional patient to
achieve single or combined recommended treatment goals. METHODS: Data from
the DURATION-3 trial was analyzed retrospectively. Treatment targets included: 1)
glycaemia (HbA1c 6.5% or fasting plasma glucose (FPG) 7 mmol/L); 2) systolic
blood pressure (SBP130 mmHg); 3) low-density lipoprotein cholesterol (LDL2.59
mmol/L); and 4) weight loss or maintenance. Hypoglycemic events were also as-
sessed. NNT was calculated for the entire intent-to-treat (ITT) population (ExQW
n233, IG n223) and for subpopulations of patients on different background ther-
apies (metformin  sulfonylurea). NNT was calculated using 1/Absolute Risk Re-
duction (percent of patients reaching goal in the ExQW treatment arm - percent of
patients reaching goal in the IG treatment arm). RESULTS: Baseline mean charac-
teristics were similar for both treatment groups: 45-48% women, age 58 years,
HbA1c 8.3%, and body mass index 32 kg/m2. Regardless of background therapy, 8
patients would need to be treated with ExQW in place of IG for 26 weeks to allow
one additional patient to attain the HbA1C goal. Five patients (ITT) would need to be
treated with ExQW vs IG to allow one additional patient to attain the HbA1c goal
with weight control and the absence of hypoglycaemia. Furthermore, 14 patients
(ITT) would need to be treated with ExQW versus IG to allow one additional patient
to reach combined HbA1c, SBP, and LDL goals. Only the FPG goal favored insulin use
with an NNT of -8 (ITT). Minor differences in the NNT values were observed be-
tween subpopulations for most goals. CONCLUSIONS: Both ExQW and IG treated
patients achieved therapeutic target goals. In this post hoc analysis the NNT results
favored ExQW for most goals.
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OBJECTIVES: Exenatide twice daily (exenatide) and liraglutide once daily, GLP-1
receptor agonists, have demonstrated improvements in glycemic outcomes for
patients with type 2 diabetes (T2D) in randomized clinical trials. We evaluated A1c
outcomes for patients initiating exenatide or liraglutide in a real-world setting.
METHODS: This retrospective cohort study used data from the Medical Quality
Improvement Consortium of ambulatory medical practices that use Centricity Of-
fice from GE Healthcare IT as their electronic medical record. Patients with T2D
receiving a prescription between Jun 2005 and May 2011 were identified (ex-
enatide61,485; liraglutide9,316). Baseline A1c measures were documented from
45 days prior to 15 days after initiating exenatide or liraglutide with follow-up
measures documented at 6 months45 days. An ANCOVA model including base-
line A1c, age, gender, concomitant glucose-lowering medications, and modified
Charlson Comorbidity Index (CCI) was used to estimate least squares mean A1c.
RESULTS: Mean(SD) age was 55(12) and 55(12), CCI 2.0(1.3) and 2.1(1.3), % male 41%
and 42% for exenatide and liraglutide patients, respectively. Baseline BMI was
38.4(7.8) and 37.9(7.7) for exenatide and liraglutude patients, respectively, who had
baseline and 6 month BMI data. Of patients not at A1c goal of7.0% at baseline, the
mean(SD) baseline A1c was 8.7(1.4) for exenatide and 8.6%(1.3) for liraglutide, and
at 6 months was 8.0%(1.6) for exenatide and 7.9%(1.6) for liraglutide; 29.8% of pa-
tients receiving exenatide and 30.8% of patients receiving liraglutide achieved7%
A1c goal at 6 months. At baseline, 47% of exenatide patients were prescribed 10
mcg BID daily; 7.7% and 83.9% of liraglutide patients were prescribed 1.2 and 1.8 mg
daily, respectively. At 6 months, 66% of exenatide patients were prescribed 10 mcg
BID daily; 11.2% and 75.4% were prescribed liraglutide 1.2 and 1.8 mg daily,
respectively. CONCLUSIONS: In this retrospective cohort study, glycemic out-
comes similarly improved for patients initiating exenatide or liraglutide.
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OBJECTIVES: The LAntus Utilisation in RUSsia Study 2 (LAURUS 2) was an obser-
vational study undertaken at 245 sites as a follow-up to the LAURUS study. It
evaluated the efficacy of switching patients with type 2 diabetes mellitus (T2DM)
from NPH insulin to insulin glargine in real-life clinical practice.METHODS: Eligible
adult patients had taken NPH and 2 oral antidiabetes drugs (OADs) for 12 months.
During the 12-week study period all patients continued OADs. The active arm
included patients whose physicians switched their basal insulin from NPH to
glargine. Patients in the control group continued on NPH. Primary end point was
change in HbA1C. Secondary end points included changes in fasting blood glucose
(FBG) and insulin dose and hypoglycaemic episodes (HEs). RESULTS: Data were
available for 2395 of the 3000 enrolled patients. Patients had a mean duration of
diabetes of 9.3  5.1 y and mean duration of insulin therapy of 2.6  2.6 y. Mean
baseline HbA1c was 9.0  1.5 % and 9.2  1.4 % in the NPH and glargine groups,
respectively. After 12 weeks, mean HbA1c decreased by 0.6 % and 1.7 % in the NPH
and glargine groups, respectively (P 0.001). HbA1c  7% was attained by 8.4% and
25.8% of patients, respectively. Mean FBG decreased 1.4 1.7 mmol/L and 3.3 2.1
mmol/L, respectively (P 0.001). Mean insulin dose increased in both groups. At
baseline,  1 severe hypoglycaemic episode was reported by 0.4% and 0.7% of NPH
and glargine patients, respectively. At 12 weeks, no glargine patients reported se-
vere hypoglycaemia, but 2 (0.8%) NPH patients had at least 1 episode.
CONCLUSIONS: In this observational study, switching patients with T2DM who
were inadequately controlled on NPH to glargine improved glycaemic control with
minimal incidence of severe hypoglycaemia.
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OBJECTIVES: Results from Canadian population-based studies show that glycae-
mic control (HbA1c 7.0%) is often not achieved in patients with either type 1
(T1DM) or type 2 (T2DM) diabetes mellitus. The aim of this prospective registry was
to identify patient characteristics associated with achieving HbA1c 7.0% in a
real-life setting 3 months after adding insulin glulisine to previous anti-hypergly-
caemic therapies. METHODS: The API registry included adult patients with T1DM
or T2DM who were receiving basal insulin ( anti-diabetic agents) and still had
HbA1C 7%. Patients for whom the treating physician had initiated the addition of
insulin glulisine within the month prior to study entry were assessed at baseline
and 3 months. Logistic regression using the backward elimination technique was
performed to identify the patient characteristics. RESULTS:HbA1C was available at
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